Inflammatory markers in early-stage breast cancer.

Abstract

e11537 Background: In a few number of studies a possible relationship between inflammatory markers and the prognosis, chemotherapy response and survival in breast cancer has been reported. The aim of this study is to point out the place of serum markers as a prognostic factor in early stage breast cancer. Methods: This study was conducted in Hacettepe University Cancer Institute. Patients operated and stage IA to III C for breast cancer between December 2009 and June 2012 were included the study. Before the any adjuvant therapy inflammation markers were studied. Results: A total of 704 patients were included in the study. The median age of the patients was 50 (25-92). 42,8% of the patients were premenopausal and 48,2% postmenopausal. The median follow up period for the whole study group was 22 months (3-287). We studied the CRP, erythrocyte sedimentation rate, B2 microglobulin, LDH, albumin, and ferritin studied and values for each marker were grouped as high and normal. There was no statistically significant difference in disease free survival and overall survival for each marker who had high and normal levels. Conclusions: We did not found any inflammatory markers as a prognostic value. However our follow up time is short and we should be wait for more mature data.

Evaluation of the Serum Levels of Interleukin-6, Interleukin-10, and C-Reactive Protein in Iraqi Women with Breast Cancer

“…Concerning C-reactive protein (CRP), Figure (3) shows a significant increase (p<0.05) in serum CRP concentration in patients with breast cancer. This is consistent with previous research [24,25,26]. CRP is produced predominantly by liver hepatocytes but also by macrophages, smooth muscle cells, endothelial cells, lymphoid cells, and adipocytes [6].…”

Impact of changes in serum lactate dehydrogenase levels on pathological response after neoadjuvant chemotherapy in patients with breast cancer

“…As BC progresses, it will change certain substances in the bloodstream. The search for appropriate circulating biomarkers can help determine the metastatic status of BC, which is of great signi cance to the treatment of BC 5 .…”